TTP and UMC have partnered up to offer two monoclonal antibody infusions as outpatient treatment for SARS -CoV-2 viral infection. The FDA has allowed Emergency Use Authorization (EUA) to high risk patients. They define High risk as the following.
High risk criteria required for bamlanizimab or casirvimab/ imdevimab infusion:
High risk is defined as patients who meet at least one of the following criteria:
Have a body mass index (BMI) ≥35
Have chronic kidney disease
Have diabetes
Have immunosuppressive disease
Are currently receiving immunosuppressive treatment
Are ≥65 years of age
Are ≥55 years of age AND have
o cardiovascular disease, OR
o hypertension, OR
o chronic obstructive pulmonary disease/other chronic respiratory disease.
Are 12 – 17 years of age AND have
BMI ≥85th percentile for their age and gender based on CDC growth charts
sickle cell disease, OR
congenital or acquired heart disease, OR
neurodevelopmental disorders, for example, cerebral palsy, OR
a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19),
OR
asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.
SCAN this QR code to fill out an online form to request medication. The UMC Ambulatory Infusion Clinic will then call the patient to schedule them if they are eligible.
To place the referral through Powerchart click on Links then Monoclonal Antibody.
